The Bundibugyo virus, a lesser-known type of Ebola, is at the center of a rapidly expanding epidemic in Africa. Previously, it caused only two small outbreaks. Now, the situation has escalated significantly in the Democratic Republic of Congo and Uganda.
Health workers are racing against time to provide supportive care. They aim to help some patients recover and focus on isolating those infected while tracing their contacts. However, vaccines and drugs that could potentially halt the virus are missing from their tools.
Scientists are deeply concerned about the scale of the epidemic. They are urgently seeking solutions. On Monday, two major nonprofit vaccine organizations announced significant funding efforts to develop vaccines for this crisis. World Health Organization experts have also recommended testing monoclonal antibodies and other drugs as possible treatments.
Researchers believe months of work will determine the effectiveness of these measures. Despite the time required, these treatments could still be essential, as the outbreak is expected to continue for some time.
Richard Hatchett, CEO of CEPI, a nonprofit supporting the development of pandemic countermeasures, stated, “It’s going to take a long, committed response to bring this outbreak under control.”
Ebola presents a unique challenge because it consists of different species of viruses. When referring to “Ebola virus,” scientists mean a species discovered in 1976 in what was then Zaire.